Best case scenario for anticancer therapy with respect to immune effectors. The cytostatic or cytotoxic agent should (A) stimulate a cell-autonomous response that facilitates recognition (and ultimately lysis) of tumor cells by immune effectors and (B) have immunostimulatory “side effects” on the host that boost the innate and/or cognate immune anticancer response. The incapacity to mediate such effects or worse, immunosuppressive side effects, can entail therapeutic failure.